ArticleBMC cancer2026
IL-8 and sCD40L predict platelet refractoriness and survival of pediatric patients with solid tumors receiving chemotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo assess inflammation, endothelial damage, and platelet activation during platelet transfusion refractoriness (PTR) in pediatric patients with solid tumors.
methodsA cohort of 36 PTR and 38 Non-PTR pediatric patients with solid tumor was enrolled. Patients received standard chemotherapy and platelet transfusion according to guidelines. Levels of inflammatory mediators (IL-1β and IL-8, etc.), endothelial damage marker (vWF), and platelet activation markers (sP-selectin, sCD40L and RANTES) in pre-transfusion plasma were quantified by flow cytometry and ELISA. Associations with PTR, bleeding events, and progression-free survival (PFS) were analyzed by multivariable regression and Cox models.
resultsThe PTR group showed significantly high levels of sP-selectin (14.1 vs. 6.0 ng/mL), sCD40L (293.4 vs. 206.2 pg/mL), vWF (231.7 vs. 162.3 µg/mL), IL-1β (67.4 vs. 38.9 pg/mL), and IL-8 (61.0 vs. 29.2 pg/mL). Multivariable analysis identified vWF (OR = 1.006), IL-1β (OR = 1.013), and IL-8 (OR = 1.021) as independent predictors of PTR. Predictive model combining these three markers with malignancy risk stratification significantly improved the predictive ability of PTR compared to clinical Model alone (AUC: 0.846 vs. 0.692, P = 0.003). Clinically, PTR patients had delayed platelet recovery (10.2 vs.7.3 days), higher bleeding (36.1% vs. 13.2%), and reduced 500-day PFS (41.5% vs. 55.2%). Elevated sP-selectin (≥ 10.1 ng/mL) and sCD40L (≥ 234.5 pg/mL) predicted bleeding. After adjustment for malignancy risk stratification, high sCD40L (HR = 3.853, 95% CI: 1.097–13.525) remained independently associated with lower PFS, whereas IL ‑ 8 showed a trend but was not statistically significant.
conclusionElevated IL-8 and sCD40L are novel predictors of PTR and survival prognostic in pediatric patients with solid tumors undergoing chemotherapy. IL-1β, IL-8 and vWF are identified as independent risk factors for PTR. sP-selectin and sCD40L are associated with increased bleeding risk, and high sCD40L is independent predictors of lower 500-day PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.